1. Home
  2. IART vs EYPT Comparison

IART vs EYPT Comparison

Compare IART & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

HOLD

Current Price

$14.92

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$13.34

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IART
EYPT
Founded
1989
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
1996
2005

Fundamental Metrics

Financial Performance
Metric
IART
EYPT
Price
$14.92
$13.34
Analyst Decision
Hold
Strong Buy
Analyst Count
7
5
Target Price
$14.33
$31.80
AVG Volume (30 Days)
1.1M
724.3K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,539,000.00
Revenue This Year
$4.39
N/A
Revenue Next Year
$3.40
$3,115.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.70
$5.57
52 Week High
$16.42
$19.11

Technical Indicators

Market Signals
Indicator
IART
EYPT
Relative Strength Index (RSI) 67.71 50.55
Support Level $12.64 $12.66
Resistance Level $16.35 $14.73
Average True Range (ATR) 0.90 0.74
MACD 0.10 -0.02
Stochastic Oscillator 84.02 58.84

Price Performance

Historical Comparison
IART
EYPT

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: